Rebuttal Cochrane Review: Is there sufficient evidence to repeal three decades of clinical research on chronic hepatitis C?

A new rebuttal over the flawed Cochrane review on DAAs downloaded and shared via Twitter by Henry E. Chang‏

Is there sufficient evidence to repeal three decades of clinical research on chronic hepatitis
Abstract
The Cochrane Collaboration has published a systematic review about the treatment chronic hepatitis C (CHC) with direct-acting antivirals (DAAs) concluding that there is no evidence either to confirm or to reject the premise that DAAs have any clinical effects and they also state that sustained virological response is an unreliable surrogate marker to assess clinical efficacy. Here we discuss the implication of the Cochrane Collaboration review at the light of the current knowledge of CHC clinical management and propose a framework for the future research.
Continue to article: https://jumpshare.com/v/YrBTvdDAAGPIv1A9bKxq

Related:

Rebuttal over Cochrane Review on DAAs 
A systematic review published by the Cochrane Collaboration suggested achieving SVR (cure) for patients using hepatitis C direct-acting antivirals (DAAs) doesn't correlate with any long term benefits. View each rebuttal and all ongoing media coverage, here.